Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes
Authors' conclusion
Metabolomics provides insight into circulating small molecules associated with loss of glycemic control and may highlight metabolic pathways contributing to treatment failure in youth-onset diabetes.
Study context
- Population
- Youths aged 10–17 years with youth-onset T2D in the TODAY study; 480 metabolites measured in fasting plasma304 with 36-month metabolomics
- Participants
- 393 participants
- Comparison
- Metabolite levels and changes vs loss of glycemic control
- Primary endpoint
- Loss of glycemic control (HbA1c ≥8% or insulin therapy)
Methodological detailsmetabolomic analysis, Cox models, elastic net regression prediction models
- Metabolomic analysis
- Cox models
- Elastic net regression prediction models
Primary result
As reported in the abstract
Loss of glycemic control occurred (mean 12.4 months)
179 of 393
Baseline metabolites associated with loss of glycemic control (q < 0.05)
33
Metabolites whose 0–36-month changes were associated with loss of glycemic control (q < 0.05)
3
Further findings
Interaction of baseline metabolites with treatment group
- Associations of hexose and xanthurenic acid with treatment failure differed by treatment randomization; higher baseline levels of these two compounds had a lower risk of treatment failure with metformin alone
Change in metabolites (0–36 months) and loss of glycemic control
- Metabolites whose changes from 0 to 36 months were associated with loss of glycemic control (q < 0.05)
- 3
- Additional metabolomic measurements after 36 months in 304 participants
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →